CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
Nicotinamide riboside +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03912220
NCT03912220Phase 2Completed
CompareCT.gov

Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration

Johns Hopkins University·interventional·Posted Apr 11, 2019·Updated Jun 12, 2024

In Brief

A Phase 2 clinical trial evaluating Nicotinamide riboside and Placebo Oral Tablet for Small Fiber Neuropathy. Completed, enrolled 45 participants across 1 site.

Detailed Summary

This study will evaluate the effects of a nutritional supplement called nicotinamide riboside in preventing small fiber nerve degeneration that is experimentally induced by applying capsaicin to skin in otherwise healthy study participants. Furthermore, the effects on nerve regeneration will also be evaluated. The results will be compared to a placebo control drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Fiber Neuropathy
CountriesUnited States
CollaboratorsAdelson Medical Research Foundation

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 11, 2019
Enrollment StartSep 1, 2020
Primary CompletionMay 1, 2023
Study CompletionMay 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.2 years ago

Interventions

Nicotinamide ribosidedrug

The experimental arm will investigate the effects of nicotinamide riboside on nerve degeneration and regeneration.

Placebo Oral Tabletdrug

Placebo drug that looks like the experimental drug, nicotinamide riboside tablets.